Autoimmune disease affects 10% of adults, most of whom are women, and two of the top five medications with the highest cost globally are used to keep these recurring conditions in remission. These medications suppress the immune system, leaving the patient exposed to increased infection and cancer risk. The general requirement for such treatments, and their side effects, has been raised as a key target for research by the PARADISE consortium patient groups. Therefore, we aim to develop a personalised prediction tool that accurately defines the patient’s risk of disease recurrence so that medication doses can be tailored and, in some cases, stopped safely. We use systemic vasculitis as a typical autoimmune disease, bringing together clinical, biomarker and smartphone derived wellbeing data to inform predictive algorithms underpinning a physician tool. Such artificial intelligence (AI) applications are coming under intense EU scrutiny, so we will co-develop an “AI transparency notice”, which will make explicit and explainable the PARADISE tool clinical outputs.